Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel
Qualigen Therapeutics (NASDAQ: QLGN) announced on September 20, 2024, that it received a notice from Nasdaq on September 11, 2024. The Nasdaq Hearings Panel has granted an extension for the company's continued listing on The Nasdaq Capital Market. This extension is subject to Qualigen demonstrating compliance with all applicable criteria for continued listing by November 19, 2024. The company stated that it is diligently working to fulfill the requirements set forth by the Panel to ensure its continued listing on Nasdaq.
Qualigen Therapeutics (NASDAQ: QLGN) ha annunciato il 20 settembre 2024 di aver ricevuto una comunicazione da Nasdaq l'11 settembre 2024. Il Pannello delle Audizioni di Nasdaq ha concesso un intervallo per la continuazione della quotazione sul Nasdaq Capital Market. Questa estensione è soggetta a Qualigen che dimostri di rispettare tutti i criteri applicabili per la continuazione della quotazione entro il 19 novembre 2024. L'azienda ha dichiarato di stare lavorando con impegno per soddisfare i requisiti stabiliti dal Pannello per garantire la sua continuazione della quotazione su Nasdaq.
Qualigen Therapeutics (NASDAQ: QLGN) anunció el 20 de septiembre de 2024 que recibió un aviso de Nasdaq el 11 de septiembre de 2024. El Panel de Audiencias de Nasdaq ha concedido una prórroga para la continuación de la cotización en el Nasdaq Capital Market. Esta prórroga está sujeta a que Qualigen demuestre el cumplimiento de todos los criterios aplicables para la continuación de la cotización antes del 19 de noviembre de 2024. La empresa declaró que está trabajando diligentemente para cumplir con los requisitos establecidos por el Panel para asegurar su continuidad en Nasdaq.
Qualigen Therapeutics (NASDAQ: QLGN)는 2024년 9월 20일 Nasdaq으로부터 2024년 9월 11일에 통지를 받았다고 발표했습니다. Nasdaq 청문 패널은 회사의 지속적인 상장을 위한 연장을 승인했습니다. 이 연장은 Qualigen이 2024년 11월 19일까지 지속적인 상장을 위한 모든 적용 기준을 준수함을 입증해야 합니다. 회사는 Nasdaq에서의 지속적 상장을 보장하기 위해 패널이 설정한 요구 사항을 충족하기 위해 열심히 작업하고 있다고 밝혔습니다.
Qualigen Therapeutics (NASDAQ: QLGN) a annoncé le 20 septembre 2024 qu'elle avait reçu un avis de Nasdaq le 11 septembre 2024. Le Panel des Audiences de Nasdaq a accordé une prolongation pour le maintien de la cotation sur le Nasdaq Capital Market. Cette prolongation est conditionnée à ce que Qualigen démontre sa conformité à tous les critères applicables pour maintenir sa cotation d'ici le 19 novembre 2024. L'entreprise a déclaré qu'elle travaille assidûment pour satisfaire aux exigences établies par le Panel afin d'assurer son maintien sur Nasdaq.
Qualigen Therapeutics (NASDAQ: QLGN) gab am 20. September 2024 bekannt, dass es am 11. September 2024 eine Mitteilung von Nasdaq erhalten hat. Das Nasdaq Hearing Panel hat eine Verlängerung für die Fortsetzung der Listung im Nasdaq Capital Market gewährt. Diese Verlängerung setzt voraus, dass Qualigen bis spätestens 19. November 2024 die Einhaltung aller anwendbaren Kriterien für die Fortsetzung der Listung nachweist. Das Unternehmen erklärte, dass es eifrig daran arbeitet, die Anforderungen des Panels zu erfüllen, um seine Fortsetzung an Nasdaq zu gewährleisten.
- Granted extension for continued Nasdaq listing until November 19, 2024
- Risk of potential delisting if compliance criteria are not met by November 19, 2024
CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced that on September 11, 2024, the Company received a notice from Nasdaq indicating that the Nasdaq Hearings Panel (“Panel”) has granted an extension for the continued listing of the Company, subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 19, 2024. The Company is diligently working to fulfill the requirements set forth by the Panel to ensure the Company’s continued listing on Nasdaq.
About Qualigen Therapeutics, Inc.
For more information about Qualigen Therapeutics, Inc., please visit www.qlgntx.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company may in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. The Company’s forward-looking statements are based on current beliefs and expectations of its management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding the timing of the offering. Any or all of the forward-looking statements may turn out to be wrong or be affected by assumptions the Company makes that later turn out to be incorrect, or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to the Company’s ability to regain compliance with Nasdaq’s continued listing requirements, including the Minimum Bid Price Requirement and the Minimum Stockholders’ Equity Requirement or its alternatives prior to October 31, 2024, the Company’s ability to file its Form 10-Q for the period ended September 30, 2024, or otherwise in the future, or otherwise maintain compliance with any other listing requirement of The Nasdaq Capital Market, the potential de-listing of the Company’s shares from The Nasdaq Capital Market due to its failure to comply with the Minimum Bid Price Requirement or the Minimum Stockholders’ Equity Requirement or its alternatives, and the Company’s ability to file its Form 10-Q for the period ended September 30, 2024, or otherwise in the future, and the other risks set forth in the Company’s filings with the Securities and Exchange Commission, including in its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. For all these reasons, actual results and developments could be materially different from those expressed in or implied by the Company’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this news release. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Investor Relations
ir@qlgntx.com.
Source: Qualigen Therapeutics, Inc.
FAQ
What extension did Qualigen Therapeutics (QLGN) receive from Nasdaq?
When does Qualigen Therapeutics (QLGN) need to comply with Nasdaq listing requirements?